Last update: Aug. 7, 2019
Poorly safe. Evaluate carefully.
Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives).
Read the Comment.
Derived from long-acting benzodiazepines with properties similar to diazepam. Indicated in the short-term treatment of anxiety disorders.
Oral administration once or twice a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data such as its low molecular weight and very long half-life (Cautreels 1980) make it likely it will trasfer into milk in quantities that could be significant.
It has very few bibliographical references and is sold in few countries.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives are preferable.
It is advisable to choose short-acting benzodiazepines and use the minimum effective dose (Rowe 2013), especially during the neonatal period and in cases of prematurity because they can accumulate in the infant during chronic use (Sachs 2013).
It is advisable to monitor drowsiness and the adequate feeding of the infant.
It is not recommended to share a bed with the baby if this medication is being taken due to an increased risk of suffocation or sudden infant death (UNICEF 2018, 2017, 2014 and 2013, Landa 2012, ABM 2008, UNICEF 2006).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM